ZTS Stock Price Today (October 2026) — Zoetis Inc. Analysis & Key Metrics 2026-10-20
Zoetis Inc. (ZTS) is trading at $80.04, up 0.57% today (as of October 2026). The stock continues to show early recovery signs above the short-term average, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $94.86 (18.5% upside).
- Volatility is low (20.99% annualized), implying relatively contained price movements for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: declining revenue trends (-0.20% YoY) alongside competitive pressures in the Drug Manufacturers - Specialty & Generic space.
ZTS Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Zoetis Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $40.65B
P/E Ratio
Forward P/E: 11.80
Revenue Growth
Year over Year
Analyst Target
+18.5% upside potential
Key Investor Questions About ZTS
What investors need to know before buying
Based on current market data, ZTS presents a overbought technical setup with challenging fundamentals.
- Technicals say: Overbought (RSI 76.68)
- Fundamentals say: Challenging (declining revenue trends)
ZTS's growth trajectory depends on its ability to expand within the Drug Manufacturers - Specialty & Generic sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - Specialty & Generic operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for ZTS investors include debt exposure and competitive dynamics in the Drug Manufacturers - Specialty & Generic industry.
- $9.26B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - Specialty & Generic.
52-Week Trading Range
Over the past year, ZTS stock traded between $68.77 and $148.30 and currently trades near the low end of that range. Big swings are less likely unless a major catalyst emerges.
Volatility & Risk Profile
With 20.99% annualized volatility and β=0.58, the stock exhibits low sensitivity to market moves—making ZTS suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
Lower institutional support combined with high short selling points to negative sentiment.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
Apple downgraded, Akamai upgraded: Wall Street's top analyst calls
Jefferies downgrades Zoetis, Elanco on pricing risk; prefers IDEXX
Jefferies Downgrades Zoetis to Hold From Buy, Price Target is $83
Zoetis’ Valuation Has Fallen Sharply, but Has the Market Overreacted?
Latest TickZen Insights
All insights →No TickZen article on ZTS yet. Our newest analysis:
Explore More Analysis for ZTS
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 5, 2026 (before the open)
Frequently Asked Questions
Common investor questions about Zoetis Inc.
Zoetis Inc. (ZTS) is currently trading at $80.04. The RSI (14-day) is at 76.7, indicating overbought territory (potentially overheated). Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $94.86 implies 18.5% upside from current levels. Volatility is moderate at 21.0% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Zoetis Inc. (ZTS): The trailing P/E ratio is 12.06, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is 11.80, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 6.72, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 9.40. Price-to-Sales is 3.20. Valuation should be compared to Drug Manufacturers - Specialty & Generic industry peers for context, as different sectors trade at different multiples.
Based on 14 analysts covering ZTS, the consensus price target is $94.86. This represents a 18.5% upside from the current price of $80.04. The range spans from a low target of $80.00 to a high target of $155.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Zoetis Inc. (ZTS) pays a dividend with a current yield of approximately 2.85%. The annualized dividend rate is $2.06 per share. The payout ratio is 33.9%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was Oct 30, 2026.
Key risks for Zoetis Inc. (ZTS) investors include: 1. Elevated debt levels (debt-to-equity of 2.94x) which could pressure margins in a rising rate environment. 2. Declining revenue (-0.2% YoY), indicating potential business headwinds. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Drug Manufacturers - Specialty & Generic sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Zoetis Inc.'s (ZTS) current debt and financial health profile: Total debt stands at $9.26B. The debt-to-equity ratio is 2.94x, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 3.08, indicating strong short-term liquidity. The quick ratio is 1.58. The company holds $1.68B in cash and equivalents. Free cash flow is positive at $2.02B, providing a cushion for debt servicing and shareholder returns.